Drug Trial Radar · NCT07164183
Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis
Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Sep 11, 2025
Primary completion
Oct 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- AlceaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective open-label randomized parallel groups study to compare efficacy and safety of Indinol Forto® 200 mg capsules and Visanne 2 mg tablets in treatment of endometriosis. This is phase 3 study, based on hypothesis of non-inferiority.
Conditions
- Endometriosis
Interventions
Indole-3-carbinolDrug
Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks
DienogestDrug
Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average daily pelvic pain score, combinedTime frame: Visit 7 (week 24)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Kazan', Russia · Not yet recruiting
Research Site
Moscow, Russia · Not yet recruiting
Research Site
Rostov-on-Don, Russia · Not yet recruiting
Research Site
Ryazan, Russia · Recruiting
Research Site
Saint Petersburg, Russia · Not yet recruiting
Research Site
Smolensk, Russia · Recruiting
Research Site
Tver', Russia · Not yet recruiting
Research Site
Yaroslavl, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.